DUBLIN--(BUSINESS WIRE)--The "Cancer Antibody Drug Conjugates Market Size, Drugs Approval, Price, Sales & Clinical Trials Insight 2030" report has been added to ResearchAndMarkets.com's offering.

Global Cancer Antibody Drug Conjugates Market Opportunity USD 70 Billion Opportunty By 2031Delhi, Oct. 30, 2025 (GLOBE ...

DUBLIN--(BUSINESS WIRE)--The "Global Bispecific Antibody Drug Conjugates Clinical Trials, Regulatory Approvals & Future Market Opportunity Outlook 2029" report has been added to ResearchAndMarkets.com ...

NetTargets employs an AI system that combines multi-omics data with neural network modelling for drug discovery.

Antibody-drug conjugates (ADCs) have revolutionized the oncology field, offering targeted cancer treatments that improve efficacy without adversely affecting healthy cells. 1 ADCs’ potential extends ...

In a landmark moment at the ESMO Congress 2025, pivotal studies have unveiled compelling evidence that a new class of ...

Zocilurtatug pelitecan (zoci), also known as ZL-1310, an investigational antibody-drug conjugate (ADC) that targets the ...

Researchers identified predictors of immunotherapy response in advanced bladder cancer, including tumor mutational burden and APOBEC mutational signature. The FDA-approved combination of Keytruda and ...

Antibody–drug conjugates (ADCs) are a class of molecules that provide a means of targeted delivery of cytotoxic agents to tumor cells. ADCs are composed of three components: a monoclonal antibody ...

Lifordi Immunotherapeutics, Inc., a clinical-stage biotech company developing antibody-drug conjugates (ADCs) for the ...

Drugs commonly used in cancer immunotherapy carry the risk for ocular adverse events, according to a speaker.In a ...